scholarly journals Glycaemic index, glycaemic load and risk of endometrial cancer: a prospective cohort study

2005 ◽  
Vol 8 (7) ◽  
pp. 912-919 ◽  
Author(s):  
Stephanie AN Silvera ◽  
Thomas E Rohan ◽  
Meera Jain ◽  
Paul D Terry ◽  
Geoffrey R Howe ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Hormone Replacement ◽  
Premenopausal Women ◽  
Glycaemic Index ◽  
Obese Women ◽  
Endometrial Cancer Risk ◽  
Glycaemic Load

AbstractObjectiveHigh-glycaemic-load diets may increase endometrial cancer risk by increasing circulating insulin levels and, as a consequence, circulating oestrogen levels. Given the paucity of epidemiological data regarding the relationship between dietary glycaemic index and glycaemic load and endometrial cancer risk, we sought to examine these associations using data from a prospective cohort study.Design, setting and subjectsWe examined the association between dietary glycaemic load and endometrial cancer risk in a cohort of 49 613 Canadian women aged between 40 and 59 years at baseline who completed self-administered food-frequency questionnaires between 1982 and 1985. Linkages to national mortality and cancer databases yielded data on deaths and cancer incidence, with follow-up ending between 1998 and 2000.ResultsDuring a mean of 16.4 years of follow-up, we observed 426 incident cases of endometrial cancer. Hazard ratios for the highest versus the lowest quartile level of overall glycaemic index and glycaemic load were 1.47 (95% confidence interval (CI) = 0.90–2.41; P for trend = 0.14) and 1.36 (95% CI = 1.01–1.84; P for trend = 0.21), respectively. No association was observed between total carbohydrate or total sugar consumption and endometrial cancer risk. Among obese women (body mass index > 30 kg m−2) the hazard ratio for the highest versus the lowest quartile level of glycaemic load was 1.88 (95% CI = 1.08–3.29; P for trend = 0.54) and there was a 55% increased risk for the highest versus the lowest quartile level of glycaemic load among premenopausal women. There was also evidence to support a positive association between glycaemic load and endometrial cancer risk among postmenopausal women who had used hormone replacement therapy.ConclusionsOur data suggest that diets with high glycaemic index or high glycaemic load may be associated with endometrial cancer risk overall, and particularly among obese women, premenopausal women and postmenopausal women who use hormone replacement therapy.

scholarly journals Endometrial Cancer Incidence in Endometriosis and Adenomyosis

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4592
Author(s):  
Marjolein Hermens ◽  
Anne M. van Altena ◽  
Iris Velthuis ◽  
Danielle C. M. van de Laar ◽  
Johan Bulten ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Endometrial Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Retrospective Cohort ◽  
Population Based ◽  
First Year ◽  
Endometrial Cancer Risk ◽  
Increased Risk

Women with histologically proven endometriosis/adenomyosis have an increased risk of ovarian cancer. Small studies show conflicting results on the endometrial cancer risk in women with endometriosis/adenomyosis. Therefore, we assessed the incidence of endometrial cancer in women with histologically proven endometriosis or adenomyosis. We performed a population-based retrospective cohort study of 129,862 women with histologically proven endometriosis/adenomyosis, matched with 132,700 women with a nevus selected from the Dutch pathology registry between 1990 and 2015. Histology results for endometrial cancer were retrieved. Crude and age-adjusted odds ratios for endometrial cancer were estimated. In the endometriosis/adenomyosis group, 1827 (1.4%) women had a histological report on endometrial cancer, and in the nevus group, 771 (0.6%) women. The age-adjusted OR for endometrial cancer was 2.58 (95%CI 2.37–2.81). After excluding the first year of follow-up, the age-adjusted OR was 0.76 (95%CI 0.63–0.92), indicating that endometrial cancer is most often found at time of histological diagnosis of endometriosis/adenomyosis. In around 20% of the endometrial cancer cases, the endometrial cancer was not recognized until after hysterectomy. Of these women, 35% had no prior (micro)curettage or biopsy. This study shows an increased incidence of endometrial cancer in women with histologically proven endometriosis and adenomyosis.

Endometrial cancer risk after fertility treatment: a population-based cohort study

2021 ◽  
Author(s):  
Sonia Guleria ◽  
Allan Jensen ◽  
Vanna Albieri ◽  
Bugge Nøhr ◽  
Kirsten Frederiksen ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Population Based ◽  
Fertility Treatment ◽  
Endometrial Cancer Risk

scholarly journals BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study

2020 ◽  
Vol 136 ◽  
pp. 169-175
Author(s):  
Sarah J. Kitson ◽  
Cemsel Bafligil ◽  
Neil A.J. Ryan ◽  
Fiona Lalloo ◽  
Emma R. Woodward ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Pathogenic Variant ◽  
Brca1 And Brca2 ◽  
Endometrial Cancer Risk

scholarly journals Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk

2006 ◽  
Vol 98 (18) ◽  
pp. 1311-1320 ◽  
Author(s):  
Timothy R. Rebbeck ◽  
Andrea B. Troxel ◽  
Yiting Wang ◽  
Amy H. Walker ◽  
Saarene Panossian ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Hormone Replacement Therapy ◽  
Cancer Risk ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Endometrial Cancer Risk

scholarly journals Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer

2015 ◽  
Vol 33 (10) ◽  
pp. 1186-1190 ◽  
Author(s):  
Polly A. Newcomb ◽  
Michael N. Passarelli ◽  
Amanda I. Phipps ◽  
Garnet L. Anderson ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Treatment Of Osteoporosis ◽  
Endometrial Cancer Risk ◽  
Patients With Cancer ◽  
Oral Bisphosphonate ◽  
Intact Uterus ◽  
The Relationship

Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

Breast cancer and diabetes.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12507-e12507
Author(s):  
Philippe Autier ◽  
Alice Koechlin ◽  
Chris Robertson ◽  
Maria Bota ◽  
Mathieu Boniol ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Serum Insulin ◽  
Glycaemic Index ◽  
Related Factors ◽  
C Peptide ◽  
Glycaemic Load ◽  
Post Menopausal

e12507 Background: Diabetes and Breast Cancer are common conditions in women and there have been various links proposed between the two conditions. Methods: To clarify the potential association between diabetes, related factors, treatments and breast cancer risk, a series of meta-analyses were carried out following PRISMA guidelines. Results: For breast cancer at all ages, the risks obtained from prospective studies were: diabetes (SRR=1.27, 95% CI (1.16, 1.39); physical activity (SRR=0.88 (0.85, 0.92)); glycaemic load (SRR=1.05, (1.00, 1.10)); glycaemic index (SRR=1.05, (1.00, 1.09)); fasting glucose (SRR=1.14, (0.94, 1.37)); serum insulin (SRR=1.11, (0.75, 1.85)); c-peptide (SRR=1.00, (0.69, 1.46)) and adiponectin (SRR=1.16, (0.93, 1.46. An increase of 5 units in BMI was associated with post-menopausal breast cancer (SRR=1.12, 95% CI (1.08, 1.16)) but not at pre-menopausal ages (SRR=0.83, 95% CI (0.72, 0.95)). Serum insulin and c-peptide were associated with breast cancer at post-menopausal ages but not at pre-menopausal. For IGF-1, Hodge’s Standardised Mean Difference (HSMD) was calculated and there was no significant association with breast cancer (HSMD=0.026, 95% CI (-0.031, 0.084). The SRR for breast cancer among users of insulin glargine was 1.08 (0.98, 1.20) and was 0.92 (0.32, 2.65) when restricted to randomized trials. Among new users, the SRR for breast cancer was 1.09 (0.98, 1.21) and there was no trend of increasing breast cancer risk with increasing duration of use of glargine (β=0.04)(p=0.52). Risk of breast cancer in a prospective cohort declined with increasing follow-up, from 1.99 (1.31, 2.03) with two years of follow-up, to 1.60 (1.10, 2.32) with 3 years, 1.50 (1.10, 2.10) with four years and 1.18 (0.84, 1.66) with five years of follow-up. There is no reduction in risk of breast cancer associated with metformin use (SRR=0.96, 95% CI (0.85, 1.08)) even for the longest duration of use (SRR=0.94, 95% CI (0.81, 1.09)). Conclusions: An association between these two common diseases could have important implications for public health with common risk factors driving further increases in both diseases yet holding the tantalizing possibility for prevention of both. Overweight/Obesity and Physcal activity appear to be common links with the two diseases.

scholarly journals Racial/Ethnic Differences in Endometrial Cancer Risk: The Multiethnic Cohort Study

2006 ◽  
Vol 165 (3) ◽  
pp. 262-270 ◽  
Author(s):  
V. W. Setiawan ◽  
M. C. Pike ◽  
L. N. Kolonel ◽  
A. M. Nomura ◽  
M. T. Goodman ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Ethnic Differences ◽  
Endometrial Cancer Risk ◽  
Multiethnic Cohort ◽  
Racial Ethnic

Hormone replacement therapy and endometrial cancer risk: A meta-analysis

1995 ◽  
Vol 85 (2) ◽  
pp. 304-313 ◽  
Author(s):  
D GRADY ◽  
T GEBRETSADIK ◽  
K KERLIKOWSKE ◽  
V ERNSTER ◽  
D PETITTI
Keyword(s):  
Endometrial Cancer ◽  
Hormone Replacement Therapy ◽  
Cancer Risk ◽  
Replacement Therapy ◽  
Meta Analysis ◽  
Hormone Replacement ◽  
Endometrial Cancer Risk

Can Aspirin Reduce the Risk of Endometrial Cancer?: A Systematic Review and Meta-analysis of Observational Studies

2016 ◽  
Vol 26 (6) ◽  
pp. 1111-1120 ◽  
Author(s):  
Dongyu Zhang ◽  
Bei Bai ◽  
Yuzhi Xi ◽  
Yuqian Zhao
Keyword(s):  
Endometrial Cancer ◽  
Dose Response ◽  
Subgroup Analysis ◽  
Meta Analysis ◽  
Hormone Replacement ◽  
Premenopausal Women ◽  
Type I ◽  
Obese Women ◽  
Case Control Studies ◽  
Statistical Heterogeneity

AbstractCurrent evidences suggest that nonsteroidal anti-inflammatory drugs can reduce the risk of several types of cancer, including breast, prostate, and colorectal cancer. However, evidences regarding the chemopreventive effect of aspirin to endometrial cancer are inconsistent. Therefore, we aimed to further explore the association. We searched PubMed, EMBASE, Web of Science, and Scopus to identify potentially eligible studies. After title/abstract screening and full-text review, we identified 7 cohort studies and 6 case-control studies. Data extraction and quality assessment were performed independently, and a random-effects model was used for data synthesis. Subgroup analysis was conducted based on obesity, hormone replacement therapy use, and cancer subtype; sensitivity analysis was conducted by pooling risk ratios of the highest dosage or longest duration of use. Dose-response relationship was assessed by a 2-stage linear dose-response model. Statistical heterogeneity was assessed by theI2value and a χ2test for the Cochrane Q statistic. In overall meta-analysis, the pooled risk ratio was 0.93 (95% confidence interval, 0.88–0.99), and no substantial statistical heterogeneity was observed (I2= 0.0%,P= 0.550). In subgroup analysis, a negative association was observed for obese women and type I endometrial cancer. Higher dosage or frequency of aspirin use was significantly associated with a reduced risk, and long-term aspirin use was protective only for obese women. In conclusion, our study suggests that the use of aspirin can reduce the risk of endometrial cancer, particularly for obese women. However, the generalizability of our conclusion should be further studied for premenopausal women and type II endometrial cancer.

Sign in / Sign up

Export Citation Format

Share Document